Asset Details
Do you wish to reserve the book?
Molecular PET and immuno-PET in gastric cancer immunotherapy: current evidence, clinical utilities, and translational barriers
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Molecular PET and immuno-PET in gastric cancer immunotherapy: current evidence, clinical utilities, and translational barriers
Do you wish to request the book?
Molecular PET and immuno-PET in gastric cancer immunotherapy: current evidence, clinical utilities, and translational barriers
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Molecular PET and immuno-PET in gastric cancer immunotherapy: current evidence, clinical utilities, and translational barriers
2026
Overview
This mini-review aims to examine how molecular PET and immuno-PET may complement tissue-based biomarkers in gastric cancer immunotherapy by enabling whole-body assessment of target expression, stromal biology, immune effector activity, and treatment-related inflammatory changes. Gastric cancer remains a major global health burden, while immunotherapy is expanding from advanced disease into perioperative and conversion settings. However, clinical benefit remains heterogeneous, and conventional biomarkers such as PD-L1, HER2, and MSI/dMMR do not fully capture spatial and temporal variation across lesions. Molecular PET broadly encompasses tracers targeting metabolism, receptors, stromal components, and immune biology, whereas immuno-PET uses radiolabeled antibodies or related scaffold proteins to visualize target distribution and, in some settings, pharmacodynamic changes in vivo . Current evidence in gastric cancer suggests potential roles for HER2-targeted PET, FAPI PET, and granzyme B PET in lesion characterization, stromal phenotyping, early response assessment, and prognostic stratification. However, PD-L1 imaging in gastric cancer remains supported mainly by preclinical data, and much of the checkpoint-imaging literature is extrapolated from non-gastric malignancies. Major barriers include limited gastric-cancer-specific prospective cohorts, heterogeneous tracer formats and imaging time points, lack of standardized quantitative thresholds, and a shortage of outcome-driven studies. Overall, molecular PET and immuno-PET should currently be viewed as promising translational tools rather than routine clinical biomarkers, with their greatest near-term value likely lying in multimodal patient stratification and early pharmacodynamic assessment.
Publisher
Frontiers Media SA,Frontiers Media S.A
